© Reuters.
MONTREAL – Paladin Labs Inc., a subsidiary of Endo International plc (OTC: OTC:), has announced the availability of XCOPRI® (cenobamate tablets) for Canadian patients as an adjunctive treatment for partial-onset seizures in adults with epilepsy. This new medication option is for those who have not found adequate control with conventional therapy.
XCOPRI, which is taken orally once daily, functions through a dual mechanism of action, aiming to reduce repetitive neuronal firing and modulate the GABAA ion channel. Its efficacy and safety were evaluated in two placebo-controlled, double-blind clinical trials, where it demonstrated a significant reduction in seizure frequency and an increased responder rate compared to placebo.
The drug has received recommendations for public reimbursement from Canadian health agencies and is marketed in the U.S. and Europe under different trademarks. Paladin Labs is working with…
